Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meeting, 52057 [E8-20644]
Download as PDF
mstockstill on PROD1PC66 with NOTICES
Federal Register / Vol. 73, No. 174 / Monday, September 8, 2008 / Notices
similar alkyltransferase inactivator, O6(4-bromothenyl) guanine is in clinical
trials in the UK.
This technology is directed to the
discovery of a new class of potent
alkyltransferase inactivators, 2-aminoO4-benzylpteridine derivatives targeted
for use in cancer treatment in
combination with chemotherapeutic
agents such as 1, 3-bis (2-chloroethyl)1-nitrosurea (BCNU) or temozolomide.
The derivatives of the present invention
inactivate the O6-alkylguanine-DNAalkyltransferase repair protein and thus
enhance activity of such
chemotherapeutic agents. Some of the
derivatives are water soluble and
possess tumor cell selectivity in
particular by inactivating
alkyltransferase in tumor cells that
overexpress folic acid receptors. The 2amino-O4-benzylpteridine derivatives
represent a promising new class of
alkyltransferase inactivator with
representatives that may be great
candidates as chemotherapy adjuvants.
Applications and Modality:
• New small molecules as
alkyltransferase inactivators based on 2amino-O4-benzylpteridine compounds.
• Promising candidates as
chemotherapy adjuvants for the
treatment of cancer.
• Therapeutic application for drug
resistant tumors where acquired
resistance is caused by O6-alkylguanineDNA alkyltransferase.
Market:
• 600,000 deaths from cancer related
diseases estimated in 2006.
• This technology involving small
molecule therapeutics for the treatment
of several cancers has a potential market
of several billion U.S. dollars.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Inventors: Robert C. Moschel (NCI) et
al.
Publication: ME Nelson, NA
Loktionova, AE Pegg, RC Moschel. 2amino-O4-benzylpteridine derivatives:
Potent inactivators of O6-alkylguanineDNA alkyltransferase. J Med Chem.
2004 Jul 15;47(15):3887–3891.
Patent Status:
• U.S. Patent Application No. 10/
585,566 filed 29 Aug 2006, claiming
priority to 06 Jan 2004 (HHS Reference
No. E–274–2003/0–US–03).
• Foreign equivalents
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Adaku
Nwachukwu, J.D.; 301–435–5560;
madua@mail.nih.gov.
VerDate Aug<31>2005
17:59 Sep 05, 2008
Jkt 214001
Dated: August 26, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E8–20651 Filed 9–5–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel EARDA.
Date: October 3, 2008.
Time: 9 a.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6100
Executive Boulevard, 4B01 CRMC, Rockville,
MD 20852.
Contact Person: Michele C. HindiAlexander, PhD, Division of Scientific
Review, National Institutes of Health, Eunice
Kennedy Shriver National Institute for Child
Health & Development, 1600 Executive
Boulevard, 5B01, Bethesda, MD 20812–7510,
(301) 435–8382, hindialm@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel; The Role of Human
Milk in Infant Nutrition and Health.
Date: October 7, 2008.
Time: 2 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6100
Executive Boulevard, 5B01, Rockville, MD
20852 (Telephone Conference Call).
Contact Person: Rita Anand, PhD,
Scientific Review Administrator, Division of
Scientific Review, National Institute of Child
Health and Human Development, NIH, 6100
Executive Blvd, Room 5B01, Bethesda, MD
20892, (301) 496–1487,
anandr@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: August 28, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–20646 Filed 9–5–08; 8:45 am]
BILLING CODE 4140–01–P
Dated: August 28, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–20644 Filed 9–5–08; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
52057
E:\FR\FM\08SEN1.SGM
08SEN1
Agencies
[Federal Register Volume 73, Number 174 (Monday, September 8, 2008)]
[Notices]
[Page 52057]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-20644]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National Institute of Child Health & Human
Development; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Child Health and Human
Development Special Emphasis Panel EARDA.
Date: October 3, 2008.
Time: 9 a.m. to 3 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6100 Executive Boulevard,
4B01 CRMC, Rockville, MD 20852.
Contact Person: Michele C. Hindi-Alexander, PhD, Division of
Scientific Review, National Institutes of Health, Eunice Kennedy
Shriver National Institute for Child Health & Development, 1600
Executive Boulevard, 5B01, Bethesda, MD 20812-7510, (301) 435-8382,
hindialm@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.864,
Population Research; 93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation Research; 93.209,
Contraception and Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: August 28, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E8-20644 Filed 9-5-08; 8:45 am]
BILLING CODE 4140-01-P